Lung Cancer
Advertisement
The Prescription Drug User Fee Act action date is expected in the third quarter of 2025.
Dr. Liu unpacks the trial results, the recent approval, and the unique biomarker testing considerations for NRG1 fusions.
It is the "first and only neoadjuvant-only immuno-oncology therapy" to show a significant OS benefit in this setting.
A multicenter study that included 21,062 patients who were seen from 2009-2021 in South Korea provided key insights.
Christopher Seder, MD, discusses the database and how it can be used for research, quality improvement, and risk ...
The 12-member board will guide the guide the patient-driven organization’s research and strategic priorities.
The study is comparing ivonescimab plus platinum-based chemotherapy with tislelizumab plus platinum-based chemotherapy.
Mara B. Antonoff, MD, FACS, discusses what could be on the horizon for surgery in stage IV lung cancer.
The bispecific antibody, which recently received FDA accelerated approval, showed a response rate of 29% in NSCLC.
Dr. Merritt shares new thoracic surgery research insights for patient selection in sublobar resection for early-stage NSCLC.
The recommendation is based on results from the phase 3 ADRIATIC trial.
The study aims to confirm safety and efficacy findings from the phase 2 QUILT 3.055 trial.
The study is evaluating a prophylactic dermatologic regimen in patients receiving amivantamab plus lazertinib.
The CHMP positive opinion is supported by results from the phase 3 PALOMA-3 study.
Dr. Seder discusses the real-world study he presented at STS 2025, which addressed key questions about long-term outcomes.
Pending discussions with the FDA, officials say there are plans to submit for regulatory approval in the second half of 2025.
Clinical Considerations Surrounding Sublobar Resection in NSCLC: Dr. Merritt Discusses Recent Review
Robert E. Merritt, MD, MBA, FACS, shares insights on his systematic review of sublobar resection and lobectomy. 
Mara B. Antonoff, MD, FACS, shares key considerations and developments in surgery for stage IV lung cancer.
However, the study findings presented at STS 2025 suggest that segmentectomy may be a “viable alternative” to lobectomy.
Despite decades of decline, "lung cancer continues to dwarf other cancers in the number of deaths," officials said.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.